Oncophage: Step to the future for vaccine therapy in melanoma

Alessandra di Pietro, Giulio Tosti, Pier F. Ferrucci, Alessandro Testori

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Heat-shock proteins (HSPs) are a group of proteins whose expression is increased when the cells are exposed to elevated temperatures or other stressful conditions. This increase in expression is transcriptionally regulated. The function of HSPs is similar in virtually all living organisms, from bacteria to humans. Their expression also occur under non-stressful conditions, simply 'monitoring' the cell's proteins, i.e., they carry old proteins to the cell's 'recycling bin' and they help newly synthesized proteins fold properly. These activities are part of a cell's own repair system. HSPs are molecular chaperones for protein molecules. They are usually cytoplasmic proteins and they perform functions in various intracellular processes. Tumour-derived HSP-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, HSPPC-96 complex, called Vitespen (formerly Oncophage®) is a HSPs-based vaccine made from individual patients' tumours with a promising role in cancer management. This vaccine has been extensively studied in Phase I and II clinical trials, showing activity on different malignancies, including gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukaemia. The vaccine has also been studied in Phase III clinical trials in melanoma and kidney cancer, showing an excellent safety profile with essentially no toxicity. Thus, HSP-based vaccines are a novel therapeutic approach with a promising role in cancer management.

Original languageEnglish
Pages (from-to)1973-1984
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Active Immunotherapy
Heat-Shock Proteins
Melanoma
Vaccines
Neoplasms
Proteins
Tumors
Phase III Clinical Trials
Phase II Clinical Trials
Peptides
Clinical Trials, Phase I
Molecular Chaperones
Kidney Neoplasms
Recycling
Condition monitoring
Bins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pancreatic Neoplasms
Non-Hodgkin's Lymphoma
Stomach Neoplasms

Keywords

  • HSPPCs
  • HSPs
  • Metastatic melanoma
  • Oncophage
  • Vitespen

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Oncophage : Step to the future for vaccine therapy in melanoma. / di Pietro, Alessandra; Tosti, Giulio; Ferrucci, Pier F.; Testori, Alessandro.

In: Expert Opinion on Biological Therapy, Vol. 8, No. 12, 12.2008, p. 1973-1984.

Research output: Contribution to journalArticle

di Pietro, Alessandra ; Tosti, Giulio ; Ferrucci, Pier F. ; Testori, Alessandro. / Oncophage : Step to the future for vaccine therapy in melanoma. In: Expert Opinion on Biological Therapy. 2008 ; Vol. 8, No. 12. pp. 1973-1984.
@article{e425391097144569bd630f281bbe8d86,
title = "Oncophage: Step to the future for vaccine therapy in melanoma",
abstract = "Heat-shock proteins (HSPs) are a group of proteins whose expression is increased when the cells are exposed to elevated temperatures or other stressful conditions. This increase in expression is transcriptionally regulated. The function of HSPs is similar in virtually all living organisms, from bacteria to humans. Their expression also occur under non-stressful conditions, simply 'monitoring' the cell's proteins, i.e., they carry old proteins to the cell's 'recycling bin' and they help newly synthesized proteins fold properly. These activities are part of a cell's own repair system. HSPs are molecular chaperones for protein molecules. They are usually cytoplasmic proteins and they perform functions in various intracellular processes. Tumour-derived HSP-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, HSPPC-96 complex, called Vitespen (formerly Oncophage{\circledR}) is a HSPs-based vaccine made from individual patients' tumours with a promising role in cancer management. This vaccine has been extensively studied in Phase I and II clinical trials, showing activity on different malignancies, including gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukaemia. The vaccine has also been studied in Phase III clinical trials in melanoma and kidney cancer, showing an excellent safety profile with essentially no toxicity. Thus, HSP-based vaccines are a novel therapeutic approach with a promising role in cancer management.",
keywords = "HSPPCs, HSPs, Metastatic melanoma, Oncophage, Vitespen",
author = "{di Pietro}, Alessandra and Giulio Tosti and Ferrucci, {Pier F.} and Alessandro Testori",
year = "2008",
month = "12",
doi = "10.1517/14712590802517970",
language = "English",
volume = "8",
pages = "1973--1984",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Oncophage

T2 - Step to the future for vaccine therapy in melanoma

AU - di Pietro, Alessandra

AU - Tosti, Giulio

AU - Ferrucci, Pier F.

AU - Testori, Alessandro

PY - 2008/12

Y1 - 2008/12

N2 - Heat-shock proteins (HSPs) are a group of proteins whose expression is increased when the cells are exposed to elevated temperatures or other stressful conditions. This increase in expression is transcriptionally regulated. The function of HSPs is similar in virtually all living organisms, from bacteria to humans. Their expression also occur under non-stressful conditions, simply 'monitoring' the cell's proteins, i.e., they carry old proteins to the cell's 'recycling bin' and they help newly synthesized proteins fold properly. These activities are part of a cell's own repair system. HSPs are molecular chaperones for protein molecules. They are usually cytoplasmic proteins and they perform functions in various intracellular processes. Tumour-derived HSP-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, HSPPC-96 complex, called Vitespen (formerly Oncophage®) is a HSPs-based vaccine made from individual patients' tumours with a promising role in cancer management. This vaccine has been extensively studied in Phase I and II clinical trials, showing activity on different malignancies, including gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukaemia. The vaccine has also been studied in Phase III clinical trials in melanoma and kidney cancer, showing an excellent safety profile with essentially no toxicity. Thus, HSP-based vaccines are a novel therapeutic approach with a promising role in cancer management.

AB - Heat-shock proteins (HSPs) are a group of proteins whose expression is increased when the cells are exposed to elevated temperatures or other stressful conditions. This increase in expression is transcriptionally regulated. The function of HSPs is similar in virtually all living organisms, from bacteria to humans. Their expression also occur under non-stressful conditions, simply 'monitoring' the cell's proteins, i.e., they carry old proteins to the cell's 'recycling bin' and they help newly synthesized proteins fold properly. These activities are part of a cell's own repair system. HSPs are molecular chaperones for protein molecules. They are usually cytoplasmic proteins and they perform functions in various intracellular processes. Tumour-derived HSP-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, HSPPC-96 complex, called Vitespen (formerly Oncophage®) is a HSPs-based vaccine made from individual patients' tumours with a promising role in cancer management. This vaccine has been extensively studied in Phase I and II clinical trials, showing activity on different malignancies, including gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukaemia. The vaccine has also been studied in Phase III clinical trials in melanoma and kidney cancer, showing an excellent safety profile with essentially no toxicity. Thus, HSP-based vaccines are a novel therapeutic approach with a promising role in cancer management.

KW - HSPPCs

KW - HSPs

KW - Metastatic melanoma

KW - Oncophage

KW - Vitespen

UR - http://www.scopus.com/inward/record.url?scp=57649220640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649220640&partnerID=8YFLogxK

U2 - 10.1517/14712590802517970

DO - 10.1517/14712590802517970

M3 - Article

C2 - 18990084

AN - SCOPUS:57649220640

VL - 8

SP - 1973

EP - 1984

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -